BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 9194034)

  • 1. Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC).
    Elias AD; Skarin AT; Leong T; Mentzer S; Strauss G; Lynch T; Shulman L; Jacobs C; Abner A; Baldini EH; Frei E; Sugarbaker DJ
    Lung Cancer; 1997 May; 17(1):147-61. PubMed ID: 9194034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Report of phase II trial of concurrent chemoradiotherapy with radical thoracic irradiation (60 Gy), infusional fluorouracil, bolus cisplatin and etoposide for clinical stage IIIB and bulky IIIA non-small cell lung cancer.
    Langer CJ; Curran WJ; Keller SM; Catalano R; Fowler W; Blankstein K; Litwin S; Bagchi P; Nash S; Comis R
    Int J Radiat Oncol Biol Phys; 1993 Jun; 26(3):469-78. PubMed ID: 8390421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study.
    Strauss GM; Herndon JE; Sherman DD; Mathisen DJ; Carey RW; Choi NC; Rege VB; Modeas C; Green MR
    J Clin Oncol; 1992 Aug; 10(8):1237-44. PubMed ID: 1321893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer.
    Deutsch M; Crawford J; Leopold K; Wolfe W; Foster W; Herndon J; Blackwell S; Yost R
    Cancer; 1994 Aug; 74(4):1243-52. PubMed ID: 8055445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer.
    Choi NC; Carey RW; Daly W; Mathisen D; Wain J; Wright C; Lynch T; Grossbard M; Grillo H
    J Clin Oncol; 1997 Feb; 15(2):712-22. PubMed ID: 9053497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accelerated induction therapy and resection for poor prognosis stage III non-small cell lung cancer.
    Rice TW; Adelstein DJ; Koka A; Tefft M; Kirby TJ; Van Kirk MA; Taylor ME; Olencki TE; Peereboom D; Budd GT
    Ann Thorac Surg; 1995 Sep; 60(3):586-91; discussion 591-2. PubMed ID: 7677484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response.
    Pourel N; Santelmo N; Naafa N; Serre A; Hilgers W; Mineur L; Molinari N; Reboul F
    Eur J Cardiothorac Surg; 2008 May; 33(5):829-36. PubMed ID: 18367406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.
    Albain KS; Rusch VW; Crowley JJ; Rice TW; Turrisi AT; Weick JK; Lonchyna VA; Presant CA; McKenna RJ; Gandara DR
    J Clin Oncol; 1995 Aug; 13(8):1880-92. PubMed ID: 7636530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of neoadjuvant chemotherapy in patients with surgically-proven, unresectable stage III non-small cell lung cancer.
    Grossi F; Pennucci MC; Serrano J; Frola C; Mereu C; Scolaro T; Ratto GB; Tixi L; Ardizzoni A
    Anticancer Res; 2002; 22(6B):3519-24. PubMed ID: 12552949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
    Betticher DC; Hsu Schmitz SF; Tötsch M; Hansen E; Joss C; von Briel C; Schmid RA; Pless M; Habicht J; Roth AD; Spiliopoulos A; Stahel R; Weder W; Stupp R; Egli F; Furrer M; Honegger H; Wernli M; Cerny T; Ris HB
    J Clin Oncol; 2003 May; 21(9):1752-9. PubMed ID: 12721251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A preoperative alternating chemotherapy and radiotherapy program for patients with stage IIIA (N2) non-small cell lung cancer.
    Takamori S; Rikimaru T; Hayashi A; Tayama K; Mitsuoka M; Fujimoto K; Horiuchi M; Hayabuchi N; Oizumi K; Shirouzu K
    Lung Cancer; 2000 Jul; 29(1):49-56. PubMed ID: 10880847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative concurrent radiation therapy and cisplatinum continuous infusion in IIIa (N2) non small cell lung cancer. A pilot study.
    Maggi G; Casadio C; Cianci R; Oliaro A; Molinatti M; Bretti S; Clerico M; Boidi-Trotti A; Rovea P
    J Cardiovasc Surg (Torino); 1994 Aug; 35(4):341-6. PubMed ID: 7929550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology.
    Ryu JS; Choi NC; Fischman AJ; Lynch TJ; Mathisen DJ
    Lung Cancer; 2002 Feb; 35(2):179-87. PubMed ID: 11804691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
    Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.
    van Meerbeeck JP; Kramer GW; Van Schil PE; Legrand C; Smit EF; Schramel F; Tjan-Heijnen VC; Biesma B; Debruyne C; van Zandwijk N; Splinter TA; Giaccone G;
    J Natl Cancer Inst; 2007 Mar; 99(6):442-50. PubMed ID: 17374834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase 2 evaluation of preoperative radiation therapy and preoperative chemotherapy with mitomycin, vinblastine, and cisplatin in patients with technically unresectable stage IIIA and IIIB non-small cell cancer of the lung. LCSG 881.
    Wagner H; Lad T; Piantadosi S; Ruckdeschel JC
    Chest; 1994 Dec; 106(6 Suppl):348S-354S. PubMed ID: 7988262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience.
    Lorent N; De Leyn P; Lievens Y; Verbeken E; Nackaerts K; Dooms C; Van Raemdonck D; Anrys B; Vansteenkiste J;
    Ann Oncol; 2004 Nov; 15(11):1645-53. PubMed ID: 15520066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment outcome of locally advanced stage IIIA/B lung cancer].
    Cicenas S; Zaliene A; Atkocius V
    Medicina (Kaunas); 2009; 45(6):452-9. PubMed ID: 19605965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vindesine-ifosfamide-platinum (VIP) induction chemotherapy in surgically staged IIIA-N2 non-small-cell lung cancer: a prospective study. Leuven Lung Cancer Group.
    Vansteenkiste JF; De Leyn PR; Deneffe GJ; Lievens YN; Nackaerts KL; Van Raemdonck DE; van der Schueren E; Lerut TE; Demedts MG
    Ann Oncol; 1998 Mar; 9(3):261-7. PubMed ID: 9602259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.